Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive clinical trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
The Lancet
COVID-19
Infectious Disease
Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)
April 23, 0206
0206
DOI: 10.1016/j.lanmic.2026.101360
Springer Nature
Pulmonary
Sepsis
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial
April 22, 0205
0205
doi: 10.1007/s00134-025-07861
No results found.
There are no results with this criteria. Try changing your search.